Monocontin

Monocontin may be available in the countries listed below.

Ingredient matches for Monocontin

Isosorbide Mononitrate

Isosorbide Mononitrate is reported as an ingredient of Monocontin in the following countries:

• Bangladesh


• India


• Sri Lanka

International Drug Name Search

Stalevo 150

See also: Generic Stalevo 100, Generic Stalevo 125, Generic Stalevo 200, Generic Stalevo 50, Generic Stalevo 75

Stalevo 150 is a brand name of carbidopa/entacapone/levodopa, approved by the FDA in the following formulation(s):

STALEVO 150 (carbidopa; entacapone; levodopa - tablet; oral)

• 
  Manufacturer: ORION
  
  Approval date: June 11, 2003
  
  Strength(s): 37.5MG;200MG;150MG
  

Has a generic version of Stalevo 150 been approved?

No. There is currently no therapeutically equivalent version of Stalevo 150 available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Stalevo 150. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pharmacologically active catechol derivatives
  Patent 5,446,194
  Issued: August 29, 1995
  Inventor(s): Backstrom; Reijo J. & Heinola; Kalevi E. & Honkanen; Erkki J. & Kaakkola; Seppo K. & Kairisalo; Pekka J. & Linden; Inge-Britt Y. & Mannisto; Pekka I. & Nissinen; Erkki A. O. & Pohto; Pentti & Pippuri; Aino K. & Pystynen; Jarmo J.
  Assignee(s): Orion-yhtyma Oy
  A compound according to formula 1 ##STR1## wherein R.sub.1 and R.sub.2 independently represent hydrogen, carbamoyl which is substituted by an alkyl of 1 to 4 carbon atoms, alkylcarbonyl of 2 to 5 carbon atoms or phenyl carbonyl, X represents halogen nitro or cyano and R.sub.3 represents ##STR2## wherein R.sub.4 represents cyano or alkylcarbonyl of 2 to 5 carbon atoms and R.sub.5 represents carbamoyl which is unsubstituted or substituted with alkyl of 1 to 8 carbon atoms or which is substituted with hydroxyalkyl of 1 to 8 carbon atoms or pharmaceutically acceptable esters and salts thereof, and a pharmaceutically acceptable carrier therefor, as well as pharmaceutical compositions containing said compounds as COMT inhibitors.
  
  Patent expiration dates:
  
  
  • October 19, 2013
    
    ✓ 
    Drug substance
  
  



• 
  Pharmaceutical composition comprising entacapone, levodopa, and carbidopa
  Patent 6,500,867
  Issued: December 31, 2002
  Inventor(s): Matti; Virkki & Kari; Vahervuo & Marja; Ritala & Marja; Partanen & Mervi; Niskanen & Jarmo; Lintulaakso & Marja; Laaksonen & Lasse; Kervinen & Sari; Kallioinen
  Assignee(s): Orion Corporation
  An oral solid fixed dose composition comprising pharmacologically effective amounts of entacapone, levodopa, and carbidopa, or pharmaceutically acceptable salts or hydrates thereof, and comprising at least one pharmaceutically acceptable excipient. The composition can be used, e.g., for the treatment of Parkinson's disease.
  
  Patent expiration dates:
  
  
  • June 29, 2020
    
    ✓ 
    Patent use: TREATMENT OF PARKINSON'S DISEASE
    ✓ 
    Drug product
  
  



• 
  Pharmaceutical composition comprising entracapone, levodopa, and carbidopa
  Patent 6,797,732
  Issued: September 28, 2004
  Inventor(s): Matti; Virkki & Kari; Vahervuo & Marja; Ritala & Marja; Partanen & Mervi; Niskanen & Jarmo; Lintulaakso & Marja; Laaksonen & Lasse; Kervinen & Sari; Kallioinen
  Assignee(s): Orion Corporation
  An oral solid fixed dose composition comprising pharmacologically effective amounts of entacapone, levodopa, and carbidopa, or pharmaceutically acceptable salts or hydrates thereof, and comprising at least one pharmaceutically acceptable excipient. The composition can be used, e.g., for the treatment of Parkinson's disease.
  
  Patent expiration dates:
  
  
  • June 29, 2020
    
    ✓ 
    Drug product
  
  

See also...

• Stalevo 150 Consumer Information (Cerner Multum)
• Stalevo 150 Advanced Consumer Information (Micromedex)
• Carbidopa/Entacapone/Levodopa Consumer Information (Wolters Kluwer)
• Carbidopa/Levodopa/Entacapone Consumer Information (Wolters Kluwer)
• Carbidopa, entacapone, and levodopa Consumer Information (Cerner Multum)
• Carbidopa, entacapone, and levodopa Advanced Consumer Information (Micromedex)

Theomol

Theomol may be available in the countries listed below.

Ingredient matches for Theomol

Theophylline

Theophylline is reported as an ingredient of Theomol in the following countries:

• Germany

International Drug Name Search

Lipoblock

Lipoblock may be available in the countries listed below.

Ingredient matches for Lipoblock

Simvastatin

Simvastatin is reported as an ingredient of Lipoblock in the following countries:

• Japan

International Drug Name Search

Carvedilolo Sigma Tau

Carvedilolo Sigma Tau may be available in the countries listed below.

Ingredient matches for Carvedilolo Sigma Tau

Carvedilol

Carvedilol is reported as an ingredient of Carvedilolo Sigma Tau in the following countries:

• Italy

International Drug Name Search

Neatenol Diuvas

Neatenol Diuvas may be available in the countries listed below.

Ingredient matches for Neatenol Diuvas

Atenolol

Atenolol is reported as an ingredient of Neatenol Diuvas in the following countries:

• Spain

Bendroflumethiazide

Bendroflumethiazide is reported as an ingredient of Neatenol Diuvas in the following countries:

• Spain

Hydralazine

Hydralazine hydrochloride (a derivative of Hydralazine) is reported as an ingredient of Neatenol Diuvas in the following countries:

• Spain

International Drug Name Search

Bernesten

Bernesten may be available in the countries listed below.

Ingredient matches for Bernesten

Clotrimazole

Clotrimazole is reported as an ingredient of Bernesten in the following countries:

• Indonesia

International Drug Name Search

Laxolac

Laxolac may be available in the countries listed below.

Ingredient matches for Laxolac

Lactulose

Lactulose is reported as an ingredient of Laxolac in the following countries:

• Bahrain


• Bangladesh

International Drug Name Search

Duragesic-50

See also: Generic Duragesic-100, Generic Duragesic-12, Generic Duragesic-25, Generic Duragesic-75

Duragesic-50 is a brand name of fentanyl, approved by the FDA in the following formulation(s):

DURAGESIC-50 (fentanyl - film, extended release; transdermal)

• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: August 7, 1990
  
  Strength(s): 50MCG/HR ^[AB]

Has a generic version of Duragesic-50 been approved?

Yes. The following products are equivalent to Duragesic-50:

FENTANYL-50 (fentanyl film, extended release; transdermal)

• 
  Manufacturer: ACTAVIS
  
  Approval date: August 20, 2007
  
  Strength(s): 50MCG/HR ^[AB]


• 
  Manufacturer: LAVIPHARM LABS
  
  Approval date: August 4, 2006
  
  Strength(s): 50MCG/HR ^[AB]


• 
  Manufacturer: MALLINCKRODT INC
  
  Approval date: February 9, 2011
  
  Strength(s): 50MCG/HR ^[AB]


• 
  Manufacturer: MYLAN TECHNOLOGIES
  
  Approval date: January 28, 2005
  
  Strength(s): 50MCG/HR ^[AB]


• 
  Manufacturer: NOVEN
  
  Approval date: October 16, 2009
  
  Strength(s): 50MCG/HR ^[AB]


• 
  Manufacturer: TEVA PHARMS
  
  Approval date: October 20, 2008
  
  Strength(s): 50MCG/HR ^[AB]


• 
  Manufacturer: WATSON LABS
  
  Approval date: August 20, 2007
  
  Strength(s): 50MCG/HR ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Duragesic-50. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Duragesic-50.

See also...

• Duragesic-50 skin patch Consumer Information (Cerner Multum)
• Fentanyl Consumer Information (Drugs.com)
• Fentanyl Consumer Information (Wolters Kluwer)
• Fentanyl Lozenge Consumer Information (Wolters Kluwer)
• Fentanyl Patch Consumer Information (Wolters Kluwer)
• Fentanyl Soluble Film Consumer Information (Wolters Kluwer)
• Fentanyl Spray Consumer Information (Wolters Kluwer)
• Fentanyl Tablet Consumer Information (Wolters Kluwer)
• Fentanyl buccal Consumer Information (Cerner Multum)
• Fentanyl citrate oral transmucosal Consumer Information (Cerner Multum)
• Fentanyl nasal Consumer Information (Cerner Multum)
• Fentanyl sublingual Consumer Information (Cerner Multum)
• Fentanyl transdermal device Consumer Information (Cerner Multum)
• Fentanyl transdermal skin patch Consumer Information (Cerner Multum)
• Fentanyl Buccal mucosa, Oromucosal Advanced Consumer Information (Micromedex)
• Fentanyl Nasal Advanced Consumer Information (Micromedex)
• Fentanyl Transdermal Advanced Consumer Information (Micromedex)
• Fentanyl Citrate AHFS DI Monographs (ASHP)

Nafti-Puren

Nafti-Puren may be available in the countries listed below.

Ingredient matches for Nafti-Puren

Naftidrofuryl

Naftidrofuryl oxalate (a derivative of Naftidrofuryl) is reported as an ingredient of Nafti-Puren in the following countries:

• Germany

International Drug Name Search